Thibaud Damy

List of Publications by Year in descending order

109 papers	8,125 citations	94433 37 h-index	49909 87 g-index
111 all docs	111 docs citations	111 times ranked	5919 citing authors

#	Article	IF	Citations
1	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	27.0	1,558
2	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
3	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
4	A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018, 39, 2799-2806.	2.2	396
5	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation, 2019, 139, 431-443.	1.6	319
6	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
7	Aortic Stenosis and Cardiac Amyloidosis. Journal of the American College of Cardiology, 2019, 74, 2638-2651.	2.8	182
8	Cardiac amyloidosis: Updates in diagnosis and management. Archives of Cardiovascular Diseases, 2013, 106, 528-540.	1.6	181
9	Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. European Heart Journal, 2016, 37, 1826-1834.	2.2	163
10	Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. European Heart Journal, 2010, 31, 2280-2290.	2.2	155
11	Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2016, 9, 126-138.	5.3	150
12	Prevalence of, Associations With, and Prognostic Value of Tricuspid Annular Plane Systolic Excursion (TAPSE) Among Out-Patients Referred for the Evaluation of Heart Failure. Journal of Cardiac Failure, 2012, 18, 216-225.	1.7	135
13	Prognostic impact of sleepâ€disordered breathing and its treatment with nocturnal ventilation for chronic heart failure. European Journal of Heart Failure, 2012, 14, 1009-1019.	7.1	120
14	High prevalence of iron deficiency in patients with acute decompensated heart failure. European Journal of Heart Failure, 2014, 16, 984-991.	7.1	113
15	Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?. European Heart Journal, 2016, 37, 3525-3531.	2.2	108
16	Myocardial Stiffness Evaluation Using Noninvasive Shear Wave Imaging in Healthy and Hypertrophic Cardiomyopathic Adults. JACC: Cardiovascular Imaging, 2019, 12, 1135-1145.	5.3	108
17	Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal, 2022, 43, 391-400.	2.2	105
18	Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> (<scp>ATTRâ€ACT</scp>) and longâ€term extension study. European Journal of Heart Failure, 2021, 23, 277-285.	7.1	103

#	Article	IF	Citations
19	Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers ofTTRgene mutations*. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 3-9.	3.0	102
20	Iron deficiency: an emerging therapeutic target in heart failure. Heart, 2014, 100, 1414-1420.	2.9	95
21	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. European Journal of Heart Failure, 2018, 20, 1664-1672.	7.1	92
22	Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. International Journal of Cardiology, 2016, 222, 562-568.	1.7	77
23	Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 158-167.	3.0	77
24	Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. Journal of Neurology, 2017, 264, 268-276.	3.6	76
25	Interplay Between Right Ventricular Function and Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2013, 61, 2153-2160.	2.8	74
26	Prevalence of sleep-disordered breathing in a 316-patient French cohort of stable congestive heart failure. Archives of Cardiovascular Diseases, 2009, 102, 169-175.	1.6	72
27	Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. European Journal of Heart Failure, 2009, 11, 818-824.	7.1	69
28	Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart, 2016, 3, e000289.	2.3	62
29	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
30	Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundamental and Clinical Pharmacology, 2004, 18, 113-123.	1.9	57
31	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021, 23, 895-905.	7.1	57
32	Identification of prognostic markers in transthyretin and AL cardiac amyloidosis*. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 194-202.	3.0	54
33	[18F]-NaF PET/CT imaging in cardiac amyloidosis. Journal of Nuclear Cardiology, 2016, 23, 846-849.	2.1	54
34	Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy. JACC: Heart Failure, 2021, 9, 115-123.	4.1	52
35	Does the physical examination still have a role in patients with suspected heart failure?. European Journal of Heart Failure, 2011, 13, 1340-1348.	7.1	49
36	Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 58.	3.3	48

#	Article	IF	Citations
37	Haematological determinants of cardiac involvement in adults with sickle cell disease. European Heart Journal, 2016, 37, 1158-1167.	2.2	45
38	The Impact of Patients With CardiacÂAmyloidosis in HFpEF Trials. JACC: Heart Failure, 2021, 9, 169-178.	4.1	39
39	Left atrial function in patients with light chain amyloidosis: A transthoracic 3D speckle tracking imaging study. Journal of Cardiology, 2018, 71, 419-427.	1.9	33
40	Early-phase myocardial uptake intensity of 99mTc-HMDP vs 99mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis. Journal of Nuclear Cardiology, 2018, 25, 217-222.	2.1	30
41	Natural history and impact of treatment with tafamidis on major cardiovascular outcomeâ€free survival time in a cohort of patients with transthyretin amyloidosis. European Journal of Heart Failure, 2021, 23, 264-274.	7.1	30
42	Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 246-255.	3.0	29
43	Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis. Clinical Research in Cardiology, 2017, 106, 331-340.	3.3	29
44	Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Failure, 2021, 8, 2380-2396.	3.1	29
45	Diagnosis and treatment of iron deficiency in patients with heart failure: Expert position paper from French cardiologists. Archives of Cardiovascular Diseases, 2014, 107, 563-571.	1.6	27
46	Practical outpatient management of worsening chronic heart failure. European Journal of Heart Failure, 2022, 24, 750-761.	7.1	27
47	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632.	2.2	27
48	Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 231-239.	7.1	26
49	Apical sparing pattern of left ventricular myocardial 99mTc-HMDP uptake in patients with transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2018, 25, 2072-2079.	2.1	23
50	How your ears can tell what is hidden in your heart: wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss inelderly-AmyloDEAFNESS pilot study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 96-100.	3.0	21
51	Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). American Journal of Cardiology, 2021, 141, 98-105.	1.6	21
52	Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure. Archives of Cardiovascular Diseases, 2018, 111, 582-590.	1.6	20
53	Adaptive servo ventilation for sleep apnoea in heart failure: the FACE study 3-month data. Thorax, 2022, 77, 178-185.	5.6	20
54	Noninvasive detection of cardiac amyloidosis using delayed enhanced MDCT: a pilot study. European Radiology, 2015, 25, 2291-2297.	4.5	19

#	Article	IF	Citations
55	Apneaâ€“hypopnea and desaturations in heart failure with reduced ejection fraction: Are we aiming at the right target?. International Journal of Cardiology, 2016, 203, 1022-1028.	1.7	18
56	Arterioâ€venous fistula for automated red blood cells exchange in patients with sickle cell disease: Complications and outcomes. American Journal of Hematology, 2017, 92, 136-140.	4.1	18
57	Myocardial iodine concentration measurement using dual-energy computed tomography for the diagnosis of cardiac amyloidosis: a pilot study. European Radiology, 2018, 28, 816-823.	4.5	18
58	Extracardiac soft tissue uptake, evidenced on early 99mTc-HMDP SPECT/CT, helps typing cardiac amyloidosis and demonstrates high prognostic value. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2396-2406.	6.4	18
59	Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study. PLoS ONE, 2016, 11, e0167213.	2.5	14
60	Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis. European Journal of Cancer, 2017, 76, 183-187.	2.8	14
61	Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group. ESC Heart Failure, 2021, 8, 1509-1521.	3.1	14
62	Pulmonary Acceleration Time to Optimize the Timing of Lung Transplant in Cystic Fibrosis. Pulmonary Circulation, 2012, 2, 75-83.	1.7	13
63	Non-vitamin K antagonist oral anticoagulants and heart failure. Archives of Cardiovascular Diseases, 2016, 109, 641-650.	1.6	12
64	A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 189-198.	3.0	12
65	Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. PLoS ONE, 2021, 16, e0257189.	2.5	12
66	Pharyngo-laryngeal involvement in systemic amyloidosis with cardiac involvement: a prospective observational study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 216-224.	3.0	11
67	Epidemiological characteristics and therapeutic management of patients with chronic heart failure who use smartphones: Potential impact of a dedicated smartphone application (report from the) Tj ETQq1 1 0.784314 rgBT /Overlock	3.1	11
68	Prevalence and prognostic value of autonomic neuropathy assessed by SudoscanÂ® in transthyretin wildâ€type cardiac amyloidosis. ESC Heart Failure, 2021, 8, 1656-1665.	3.1	11
69	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet Journal of Rare Diseases, 2021, 16, 204.	2.7	11
70	Diagnostic Value of Extracellular Volume Quantification and Myocardial Perfusion Analysis at CT in Cardiac Amyloidosis. Radiology, 2021, 300, 326-335.	7.3	11
71	History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis. ESC Heart Failure, 2021, 8, 5501-5512.	3.1	11
72	Assessing Cardiac Amyloidosis SubtypesÂby Unsupervised Phenotype Clustering Analysis. Journal of the American College of Cardiology, 2021, 78, 2177-2192.	2.8	11

#	Article	IF	Citations
73	Pulmonary Hemodynamic Responses to Inhaled NO in Chronic Heart Failure Depend on PDE5 G(â€1142)T Polymorphism. Pulmonary Circulation, 2011, 1, 377-382.	1.7	10
74	Echocardiographic Evaluation of Left Ventricular Filling Pressure in Patients With Heart Failure With Preserved Ejection Fraction: Usefulness of Inferior Vena Cava Measurements and 2016 EACVI/ASE Recommendations. Journal of Cardiac Failure, 2020, 26, 507-514.	1.7	10
75	Cohort profile: FACE, prospective follow-up of chronic heart failure patients with sleep-disordered breathing indicated for adaptive servo ventilation. BMJ Open, 2020, 10, e038403.	1.9	10
76	Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis. Sleep, 2016, 39, 1333-1341.	1.1	9
77	Association between hearing loss and hereditary ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 234-242.	3.0	9
78	Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 469-477.	4.0	9
79	Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment. Journal of Clinical Medicine, 2021, 10, 4868.	2.4	9
80	Left ventricular assessment in patients with systemic light chain amyloidosis: a 3-dimensional speckle tracking transthoracic echocardiographic study. International Journal of Cardiovascular Imaging, 2019, 35, 845-854.	1.5	8
81	Influence of centre expertise on the diagnosis and management of hypertrophic cardiomyopathy: A study from the French register of hypertrophic cardiomyopathy (REMY). International Journal of Cardiology, 2019, 275, 107-113.	1.7	8
82	Frailty in Wild-Type Transthyretin Cardiac Amyloidosis: The Tip of the Iceberg. Journal of Clinical Medicine, 2021, 10, 3415.	2.4	8
83	Development of a Human Model for the Study of Effects of Hypoxia, Exercise, and Sildenafil on Cardiac and Vascular Function in Chronic Heart Failure. Journal of Cardiovascular Pharmacology, 2015, 66, 229-238.	1.9	7
84	Impact of Pulmonary Hypertension on Outcome in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. Clinical Research in Cardiology, 2017, 106, 542-550.	3.3	7
85	Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. ESC Heart Failure, 2020, 7, 727-736.	3.1	7
86	Extracorporeal membrane oxygenation support in acute circulatory failure: A plea for regulation and better organization. Archives of Cardiovascular Diseases, 2019, 112, 441-449.	1.6	6
87	Causes and consequences of cardiac fibrosis in patients referred for surgical aortic valve replacement. ESC Heart Failure, 2019, 6, 649-657.	3.1	6
88	Coronavirus disease vaccination in heart failure: No time to waste. Archives of Cardiovascular Diseases, 2021, 114, 434-438.	1.6	6
89	First symptoms and health care pathways in hospitalized patients with acute heart failure: <scp>ICPS2</scp> survey. A report from the Heart Failure Working Group (GICC) of the French Society of Cardiology. Clinical Cardiology, 2021, 44, 1144-1150.	1.8	6
90	Vaccination for Respiratory Infections in Patients with Heart Failure. Journal of Clinical Medicine, 2021, 10, 4311.	2.4	6

#	Article	IF	Citations
91	Sleep-disordered breathing in chronic heart failure: development and validation of a clinical screening score. Sleep Medicine, 2015, 16, 1094-1101.	1.6	5
92	Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 961-975.	3.0	5
93	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. Journal of Clinical Medicine, 2022, 11, 2976.	2.4	5
94	Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation. Journal of Clinical Medicine, 2021, 10, 4888.	2.4	4
95	Prescription, Compliance, and Burden Associated with Salt-Restricted Diets in Heart Failure Patients: Results from the French National OFICSel Observatory. Nutrients, 2022, 14, 308.	4.1	4
96	Prevalence and determinants of iron deficiency in cardiac amyloidosis. ESC Heart Failure, 2022, 9, 1314-1327.	3.1	4
97	Characterization of untyped cardiac amyloidosis by mass spectrometry in a patient with Gly6Ser transthyretin polymorphism in fatal cardiogenic shock. Archives of Cardiovascular Diseases, 2014, 107, 706-708.	1.6	3
98	Quantification of Myocardial Enhancement on Cine-MRI: Diagnostic Value in Cardiac Amyloidosis. Academic Radiology, 2019, 26, e98-e107.	2.5	3
99	Development and Validation of a New Tool to Assess Burden of Dietary Sodium Restriction in Patients with Chronic Heart Failure: The BIRD Questionnaire. Nutrients, 2018, 10, 1453.	4.1	2
100	Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. Future Cardiology, 2022, 18, 165-172.	1.2	2
101	Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 79-91.	3.0	2
102	Deleterious effect of right ventricular pacing in patients with cardiac transthyretin amyloidosis: potential clinical benefit of cardiac resynchronization therapy. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.6	1
103	Reply to the letter regarding the article â€˜Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (<scp>ATTRâ€ACT</scp>) and longâ€term extension studyâ€™. European Journal of Heart Failure, 2021, 23, 1057-1058.	7.1	1
104	Severe Heart Failure Associated With Tachycardia-Induced Cardiomyopathy Due to Incessant Atrioventricular Re-Entrant Tachycardia. JACC: Case Reports, 2021, 3, 479-483.	0.6	1
105	Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0, , 1-11.	3.0	1
106	Author's reply. Journal of Cardiology, 2018, 72, 368.	1.9	0
107	Aortic stenosis and amyloid heart disease: â€˜the 2A dangerous liaisonsâ€™. European Heart Journal, 2020, 41, 2815-2815.	2.2	0
108	Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: a clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY). Clinical Research in Cardiology, 2021, , 1.	3.3	0

#	Article	IF	Citations
109	Arterio-Venous Fistula Is an Applicable Vascular Access for Erythracytapheresis in Patients with Sickle Cell Disease. Blood, 2016, 128, 4856-4856.	1.4	0